pharmaphorum

OCTOBER 27, 2020

Things were looking promising for the project as recently as last month, when BioSig said it was doubling the size of the study from 40 to 80 patients and hiring a contract manufacturer to produce supplies for a phase 3 trials programme. BioSig has previously said it was considering a spin-out of ViralClear.

Drug Trials 98

Drug Trials Trials Drugs Contract Manufacturing 98

pharmaphorum

JANUARY 6, 2021

million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. In 2019 the Danish company also licensed a preclinical-stage, small-molecule candidate for NASH from Japan’s UBE.

Gene Silencing 66

Gene Silencing Gene RNA Contract Manufacturing 66

The Pharma Data

NOVEMBER 17, 2021

Pfizer has begun and will continue to invest up to roughly$ 1 billion of its own finances to support the manufacturing and distribution of this investigational treatment seeker. PF-07321332 inhibits viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

HR 52

HR Manufacturing Contract Manufacturing Licensing 52

The Pharma Data

NOVEMBER 19, 2021

.” PF-07321332 is designed to block the exertion of the SARS-CoV-2-3CL protease, an enzyme that the coronavirus needs to replicate, at a stage known as proteolysis-which occurs before viral RNA replication.

HR 52

HR Contract Manufacturing Manufacturing Clinical Trials 52

The Pharma Data

MARCH 22, 2022

Pfizer continues to invest to support the manufacturing and distribution of PAXLOVID, including exploring potential contract manufacturing options. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

In-Vitro 52

In-Vitro Contract Manufacturing Manufacturing Development 52

Pfizer

DECEMBER 13, 2021

1 They collaborated on methods to purify the RNA using a process called tangential flow filtration, which removes unneeded materials. All the while, they've continued partnering with contract manufacturing organizations (CMOs) to further increase production as they work toward their goal of 3 billion doses in 2021.

Manufacturing 52

Manufacturing Vaccine Vaccination Production 52

pharmaphorum

JANUARY 7, 2021

The biotech would likely struggle to supply without the help of its new big pharma partner, although it has been expanding its production capacity in the last few weeks with the help of contract manufacturers like Wacker and Fareva.

Vaccine 105

Vaccine Vaccination Contract Manufacturing Development 105